REZOLUTE, INC. Debt Conversion, Converted Instrument, Amount
REZOLUTE, INC. (RZLT) reported Debt Conversion, Converted Instrument, Amount of $6.14 million for the 12-month period ending 2019-06-30, per its 10-K filed 2019-09-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2019-09-10
- REZOLUTE, INC. debt conversion, converted instrument, amount for the quarter ending 2019-06-30 was -$117.00.
- REZOLUTE, INC. debt conversion, converted instrument, amount for the quarter ending 2018-12-31 was $6.17M.
- REZOLUTE, INC. debt conversion, converted instrument, amount for fiscal 2019 was $6.14M.
| Period end | Debt Conversion, Converted Instrument, Amount 1 month | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$117.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-10 | $6.14M 10-K · filed 2019-09-10 | ||
| 2019-03-31 | $6.14M 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $6.17M 10-Q · filed 2019-02-14 | |||
| 2014-03-31 | $4.28M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |